Voices For Life

Voices for Life is an e-publication dedicated to informing and educating the public on pro-life and pro-family issues. We cover issues from conception until natural death, as well as all family life issues.

Tuesday, October 27, 2015

Planned Parenthood Flouts FDA Guidelines for RU-486




by Jonathan Abbamonte
Population Research Institute


Planned Parenthood and the abortion-provider Tucson Women's Center spearheaded a lawsuit to strike down an Arizona law requiring doctors to abide by FDA guidelines when administering a “drug or substance” used to induce abortion.

And they prevailed.

An Arizona state court ruled in their favor, a ruling which allows doctors to continue off-label usage of the risky mifepristone (RU-486) drug. These are protocols that Planned Parenthood claims are considered “best practice,” but which the FDA has not approved.

At the time of the ruling, the new Arizona law was not in effect. Late last year the Ninth Circuit Court of Appeals placed an injunction on the law, calling it “wholly unnecessary.” Since the U.S. Supreme Court refused to review the case, it was effectively in limbo until now.

The Maricopa County Superior Court, which issued the ruling, claims that requiring doctors to administer chemical abortion drugs according to FDA guidelines is unconstitutional. The law was originally passed by the Arizona state legislature and signed into law by then-Governor Jan Brewer in 2012. It was designed to protect women by clamping down on inherently risky later-gestation-age chemical abortions.

The maternal health risks associated with RU-486 are, in many circumstances, serious, even life-threatening…

Read more HERE.

The Population Research Institute is a non-profit research group whose goals are to expose the myth of overpopulation, to expose human rights abuses committed in population control programs, and to make the case that people are the world’s greatest resource. Our growing, global network of pro-life groups spans over 30 countries.  


No comments:

Post a Comment